Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Fig. 3

CD16 high expression on CD11b+myeloid cells was good prognostic marker for CRC patients’ survival. Kaplan-Meier analysis of overall survival (OS) and disease free survival (DFS) was performed in CD16+ group and CD16low/− group, p values were calculated by log-rank test (n = 65 in CD16+ group and n = 69 in CD16low/− group)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us